Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.97Concord Biotech demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company efficiently manages its debt and showcases robust growth in revenue, operating profit, and earnings per share. High profitability ratios, such as ROCE, ROE, and ROA, indicate effective use of capital and assets. However, the company shows low efficiency ratios, particularly in fixed asset and capital turnover, suggesting potential areas for improvement. While liquidity is generally sound, the cash ratio is relatively low. Overall, Concord Biotech exhibits a healthy financial profile, driven by solid growth and profitability, though improvements in asset utilization could further enhance its performance.
Health Score : 7.97Concord Biotech demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company efficiently manages its debt and showcases robust growth in revenue, operating profit, and earnings per share. High profitability ratios, such as ROCE, ROE, and ROA, indicate effective use of capital and assets. However, the company shows low efficiency ratios, particularly in fixed asset and capital turnover, suggesting potential areas for improvement. While liquidity is generally sound, the cash ratio is relatively low. Overall, Concord Biotech exhibits a healthy financial profile, driven by solid growth and profitability, though improvements in asset utilization could further enhance its performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
58.97
Industry Median
7.70
Small Cap Median
7.70
P/E RATIO
59.51
P/B RATIO
7.69
Industry Median
1.53
Small Cap Median
1.53
P/S RATIO
13.04
Industry Median
3.62
Small Cap Median
3.62
Others
PEG RATIO
0.00
EV/EBITDA RATIO
32.81
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1484.3 as on Sep 1, 2026.
Growth Score : 10.00Concord Biotech demonstrates strong growth across all key metrics, including revenue, operating profit, EPS, assets, and net income. This consistent growth indicates a robust business model, effective management strategies, and a favorable market position. The company is expanding its operations and profitability, positioning it well for future success and increased shareholder value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 15.75 | 19.64 | 19.23 | 17.99 | -12.08 |
| Operating Profit Growth Rate | -17.43 | 27.41 | 25.58 | 17.13 | -27.47 |
| Earnings Per Share (EPS) Growth | -25.67 | -87.52 | 28.32 | 20.61 | -29.79 |
| Asset Growth Rate | 10.99 | 15.31 | 12.35 | 19.58 | 9.88 |
| Net Income Growth Rate | -25.53 | 37.14 | 28.33 | 20.78 | -30.38 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Concord Biotech Ltd | 7.97 | 59.51 | Neutral | 367.00 | 25.17 | 259.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤14th Nov 25
Q2 & H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Concord Biotech Ltd is a leading Indian biopharmaceutical company focused on fermentation-based Active Pharmaceutical Ingredients (APIs) and Contract Research and Manufacturing Services (CRAMS). Specializing in immunosuppressants, oncology, and anti-fungal segments, the company serves both domestic and international markets, known for its strong R&D capabilities and global regulatory approvals.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Concord Biotech Ltd's P/E ratio (TTM) is 58.97, compared to the industry median of 7.70 and large cap median of 7.70.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Concord Biotech Ltd's P/B ratio is 7.69, compared to the industry median of 1.53 and large cap median of 1.53.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Concord Biotech Ltd's P/S ratio is 13.04, compared to the industry median of 3.62 and large cap median of 3.62.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Concord Biotech Ltd's PEG ratio is 1.80.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Concord Biotech Ltd's EV/EBITDA ratio is 32.81.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Concord Biotech Ltd's ROE is 12.84%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Concord Biotech Ltd's ROA is 16.42%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Concord Biotech Ltd's ROCE is 18%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Concord Biotech Ltd's operating margin is 34.79%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Concord Biotech Ltd's net margin is 24.55%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Concord Biotech Ltd's current ratio is 4.07.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Concord Biotech Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Concord Biotech Ltd's interest coverage ratio is 496.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Concord Biotech Ltd's DPS is ₹7.48.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Concord Biotech Ltd's EPS is -29.79.
(Source line: "Ratios as of 24 Oct 2026, based on last traded price of ₹1484.30. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1984
Headquarters: Ahmedabad, Gujarat
Core Offerings: Fermentation-based APIs (Immunosuppressants), Oncology APIs, Anti-fungal APIs, Contract Research and Manufacturing Services (CRAMS)
Stock Listing: NSE (CONCORDBIO), BSE (543960)
Promoter: Sudhir Valia / Valia Group
Concord Biotech was incorporated in 1984, founded by Mr. Sudhir Valia. The company commenced commercial operations in 1986, establishing its niche in fermentation-based APIs. Over decades, it expanded its product portfolio, achieving global regulatory approvals and establishing a significant presence in key therapeutic areas like immunosuppressants and oncology. The company successfully completed its Initial Public Offering (IPO) and listed on Indian stock exchanges in August 2023.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Immunosuppressant APIs | 83.92% (FY23) | Operating Profit |
| Anti-Fungal APIs | 9.24% (FY23) | Operating Profit |
| Oncology APIs | 5.17% (FY23) | Operating Profit |
| Other APIs & CRAMS | 1.67% (FY23) | Operating Profit |
Immunosuppressant APIs: A significant revenue driver, Concord Biotech manufactures and supplies a range of APIs for drugs used to prevent organ rejection in transplant patients.
Oncology APIs: Developing and producing active pharmaceutical ingredients for cancer treatment, a growing and critical segment.
Anti-fungal APIs: Provides APIs for various anti-fungal medications, catering to a global demand for infection control.
Contract Research and Manufacturing Services (CRAMS): Offers specialized contract manufacturing for fermentation-based products, leveraging its expertise and infrastructure for other pharmaceutical companies.
Mr. Sudhir Valia (Chairman & Non-Executive Director): A seasoned professional with extensive experience in the pharmaceutical sector, he founded Concord Biotech and has been instrumental in its growth and strategic direction.
Initial Public Offering (IPO) in August 2023.
The Concord Biotech Ltd share price today is ₹1484.30 on NSE (CONCORDBIO), as of 24 Oct 2026.
As of 24 Oct 2026, Concord Biotech Ltd share price is ₹1484.30, with previous close ₹1484.30. Today's range is ₹1484.30 to ₹1484.30. The 52-week range is ₹N/A to ₹N/A.
As of today, Concord Biotech Ltd's market cap is ₹13,759.46 crore (Mid Cap).
Concord Biotech Ltd's current P/E ratio is 58.97, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Concord Biotech Ltd's current P/B ratio is 7.69.
Concord Biotech Ltd's current dividend yield is 0.50%. Last dividend of ₹5.00 per share was declared on Declared on 23-May-2024 (subject to AGM approval).
Concord Biotech Ltd's EPS (TTM) is ₹-29.79.
Concord Biotech Ltd is a leading Indian biopharmaceutical company focused on fermentation-based Active Pharmaceutical Ingredients (APIs) and Contract Research and Manufacturing Services (CRAMS). Specializing in immunosuppressants, oncology, and anti-fungal segments, the company serves both domestic and international markets, known for its strong R&D capabilities and global regulatory approvals.
Concord Biotech Ltd is promoted by Sudhir Valia / Valia Group, holding 44.08% as of 24 Oct 2026.
Concord Biotech Ltd is listed on NSE (CONCORDBIO) and BSE (543960). Its next quarterly results are expected on Q1 FY25 (July/August 2024).
Dividend Per Share (DPS)
